Globus Medical Q2 Earnings Top Consensus, Revenue Hits $745.3M

Globus Medical reported Q2 non-GAAP EPS of 86c, beating consensus of 75c. Revenue was $745.3M, also exceeding consensus of $742.73M. The US Spine business grew 5.7%, while Enabling Technologies showed a modest bounce back. The company plans to accelerate deal timelines and increase investment in robotic-assisted surgery.

Globus Medical (NYSE: GMED) reported robust financial results for the second quarter of 2025, with revenue and non-GAAP EPS exceeding analyst expectations. The company's Q2 2025 revenue was $745.3 million, up 18.4% year-over-year, surpassing the consensus estimate of $742.73 million [1]. Non-GAAP diluted EPS came in at $0.86, beating the consensus of $0.75.

The company's U.S. Spine business demonstrated particular strength, growing 5.7% (7.4% day-adjusted), while Enabling Technologies, likely referring to their robotic surgery platform, showed a modest bounce back. Globus Medical's management has expressed a commitment to accelerating deal timelines in this segment and increasing investment in robotic-assisted surgery.

Globus Medical reaffirmed its 2025 guidance, projecting revenue between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30. The company's strong Q2 performance reflects its continued focus on new product launches, organic growth, competitive rep recruiting, and robotic account pull-through. The results also indicate the company's operational efficiency and commitment to profitable growth.

The company's GAAP net income of $202.8 million, up 538.7% year-over-year, was driven by a $110.6 million bargain purchase gain and a $34.8 million tax benefit. However, the more telling non-GAAP EPS of $0.86 represents a 14.1% increase year-over-year and reached a quarterly record.

Globus Medical's cash flow metrics also showed $77.9 million from operations and $31.3 million in non-GAAP free cash flow. The company completed its Nevro acquisition and has begun working on synergy identification and execution.

Management's commentary suggests confidence in continued momentum through the second half of 2025, with an emphasis on operational efficiency and profitable growth. The company's results reflect its long-term strategy of new product launches, organic growth, competitive rep recruiting, and robotic account pull-through.

References:
[1] https://www.stocktitan.net/news/GMED/globus-medical-reports-second-quarter-2025-cu3gq1a0m5d2.html